EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The UK vaccine innovation pathway

Sarah Danson iD, Robert P Jones, Kristina Duggleby, Gillian Rosenberg, Matthew Hallsworth, Maria Koufali

Immunotherapy Advances · 31.12.2025 · 6 (1)

DOI: 10.1093/immadv/ltaf032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 15.11.2025. Verfasst von Sarah Danson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer vaccines offer transformative potential in oncology, especially with advances in mRNA technologies. To accelerate advances in cancer vaccine research and capitalize on its COVID-19 vaccine leadership, the UK Government has launched the UK Vaccine Innovation Pathway (VIP) through a partnership between the National Institute for Health and Care Research (NIHR), NHS England, and pharmaceutical partners. Its innovative approaches to trial delivery have enabled a 500% increase in patient recruitment with 33 trials open or recently closed across 85 sites and 11 cancer types. Working alongside the Cancer Vaccine Launchpad (CVLP), which pre-screens patients across 55 NHS sites, VIP offers streamlined trial set-up, decentralized delivery, and equity-focused design. The UK’s approach aligns scientific innovation with rapid clinical deployment, creating a scalable, patient-centred model for delivering individualized therapies. This article outlines the strategic framework, outcomes, and lessons from the VIP and CVLP to inform future national strategies in cancer vaccine deployment.

Schlagwörter

Stichwörter der Autor:innen

cancer vaccinesindividualized therapies

Autor:innen und Institutionen

  • Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom.
  • Department of Oncology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
  • UK Vaccine Innovation Pathway, National Institute for Health and Care Research, London, United Kingdom.
  • Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
  • NHS Cancer Programme, NHS England, London, United Kingdom.

ORCID-Profile: Sarah Danson

Zitieren

APA

Danson, S., Jones, R. P., Duggleby, K., Rosenberg, G., Hallsworth, M., & Koufali, M. (2025). The UK vaccine innovation pathway. Immunotherapy Advances, 6(1). https://doi.org/10.1093/immadv/ltaf032

Vancouver

Danson S, Jones RP, Duggleby K, Rosenberg G, Hallsworth M, Koufali M. The UK vaccine innovation pathway. Immunotherapy Advances. 2025;6(1). doi:10.1093/immadv/ltaf032

BibTeX
@article{Danson2025,
  author = {Danson, Sarah and Jones, Robert P and Duggleby, Kristina and Rosenberg, Gillian and Hallsworth, Matthew and Koufali, Maria},
  title = {The UK vaccine innovation pathway},
  journal = {Immunotherapy Advances},
  year = {2025},
  volume = {6},
  number = {1},
  doi = {10.1093/immadv/ltaf032}
}
Kostenlos starten →